Maintenance therapy with olaparib and bevacizumab extended survival for women with newly diagnosed advanced ovarian cancer with homologous recombination deficiency, according to study results.

The combination of the PARP inhibitor olaparib and the PD-1 inhibitor pembrolizumab showed initial antitumor activity with no new safety signals in a molecularly matched, tumor-agnostic trial ...

Olaparib is recommended, within its marketing authorisation, as an option for treating HER2-negative locally advanced or metastatic breast cancer with germline BRCA1 or BRCA2 mutations in adults who ...

Olaparib, a PARP inhibitor, shows promise as a maintenance therapy for patients with newly diagnosed advanced-stage, high-grade serous ovarian cancer who are HRD-positive but BRCA wild-type.

Treatment arms (SOC [once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin], cediranib, olaparib, or cediranib/olaparib) were equally randomized. A preplanned interim futility analysis ...

SAN ANTONIO — Nearly 10 years along patients with high-risk BRCA-positive breast cancers who had been treated with the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib (Lynparza ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2 ...

Please provide your email address to receive an email when new articles are posted on . Olaparib reduced risk for invasive and distant DFS compared with placebo. A lower percentage patients who ...

At six years, 79.6% of olaparib-treated patients remained free of invasive recurrence and 83.5% remained free of distant recurrence, compared to 70.3% and 75.7%, respectively, in the placebo group.

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease progression or death in ovarian cancer patients without BRCA mutations ...

The anti-cancer drug olaparib may be effective in treating biochemically recurrent prostate cancer without accompanying hormone therapy for men who have mutations in genes such as BRCA2 ...